Ali Fahim

Mr. Ali Fahim

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OGOlivia Erline Gilbert
Olivia Erline Gilbert
HFHenry Forbes Fowler
Henry Forbes Fowler
AMAsish Madarapu
Asish Madarapu
MRMax Reed
Max Reed
AFAli Fahim
Ali Fahim
DHDominique M. O. Higgins
Dominique M. O. Higgins
Glioblastoma (GBM) remains the most common and most aggressive primary malignant brain tumor in adults, and despite maximal safe resection with adjuvant radiotherapy (RT) and temozolomide (TMZ), median overall survival remains 12–15 months with near-universal recurrence. Ferroptosis, an iron-dependent form of regulated cell death driven by the accumulation of lipid peroxides, has emerged as a distinctive vulnerability in GBM, whose iron-avid phenotype, polyunsaturated fatty acid-rich milieu, and high oxygen consumption create a permissive substrate for lipid peroxidation. In this review, we synthesize preclinical evidence positioning ferroptosis as a determinant of GBM radiosensitivity and evaluate strategies to exploit it. We first outline core ferroptosis biology and GBM-specific modifiers of ferroptotic susceptibility, including TFR1-mediated iron import, grade-dependent glutathione peroxidase 4 (GPX4) expression, acyl-coenzyme A synthetase long-chain family member 4 (ACSL4) levels, transsulfuration, NRF2, p53, non-coding RNAs, and the relative resistance of mesenchymal tumors and glioma stem cells. We then examine mechanisms of radiation-induced ferroptosis, in which RT upregulates ACSL4 and depletes glutathione (GSH) while simultaneously provoking adaptive responses that induce the cystine transporter solute carrier family 7 member 11 (SLC7A11) and GPX4, alongside hypoxia-, IFI16/HMOX1-, and lncRNA-mediated programs that sustain radioresistance, noting that recurrent tumors display a ferroptosis-primed profile after chemoradiation. Radiosensitization strategies are reviewed across pharmacologic ferroptosis inducers (classes I-IV), repurposed agents, NRF2 inhibition, genetic targeting of ferroptosis mediators, and blood–brain barrier-penetrant nanoplatforms that couple iron delivery, high-Z radiation deposition, and antioxidant disruption. We further address the immunologic consequences of ferroptosis within the immunosuppressive GBM microenvironment, the countervailing problem of radiation-induced brain injury and candidate neuroprotective approaches, the potential convergence of FLASH RT with iron-dependent differential sparing, and comparative evidence of ferroptosis-RT synergy in other treatment-resistant malignancies. Finally, we appraise candidate biomarkers and ferroptosis-related gene signatures, and close by addressing open questions and current translational hurdles facing the field.

1 January 2026 in Ferroptosis and Oxidative Stress
Verified
Journal Article
Open access
PDF file
OGOlivia Erline Gilbert
Olivia Erline Gilbert
SJSebastian John
Sebastian John
AFAli Fahim
Ali Fahim
DHDominique M.O. Higgins
Dominique M.O. Higgins
Ferroptosis sensitivity in cancer cells is directly governed by cellular metabolism and nutritional inputs, including amino acid availability, lipid composition, and redox homeostasis. This suggests that dietary interventions might systemically shift the metabolic landscape of tumors toward ferroptotic susceptibility. Specifically, dietary restriction of methionine and cysteine, iron supplementation, selenium or lipid modulation, ketogenic diets, and fasting-mimicking regimens each target distinct aspects of the ferroptosis regulatory network and offer pharmacologic parallels that converge on complementary mechanisms. In glioblastoma (GBM), preclinical studies demonstrate that restriction of dietary methionine and cysteine sensitizes gliomas to ferroptosis and synergizes with glutathione peroxidase 4 (GPX4) inhibitors, while radiation itself triggers ferroptotic cell death. Emerging data extend these principles across multiple tumor types, including pancreatic, gastric, esophageal, and colorectal cancers, as well as leukemia, suggesting broad applicability. Here, we synthesize the rapidly growing literature that links these nutritional interventions to ferroptosis sensitization in cancer, with particular focus on GBM as a paradigmatic treatment-resistant malignancy.